Page last updated: 2024-11-11
22-hydroxyacuminatine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
22-hydroxyacuminatine: cytotoxic; isolated from Camptotheca acuminata; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Camptotheca | genus | A plant genus of the family NYSSACEAE (sometimes classified in the CORNACEAE family). It is a source of CAMPTOTHECIN.[MeSH] | Nyssaceae | The sour gum family of the order Cornales.[MeSH] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9883320 |
CHEMBL ID | 205175 |
MeSH ID | M0496362 |
Synonyms (3)
Synonym |
---|
22-hydroxyacuminatine |
CHEMBL205175 |
19-(hydroxymethyl)-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15,17,19-nonaen-14-one |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (8)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID321563 | Antiproliferative activity against human HT29 cells at 2 uM after 96 hrs | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 | Synthesis and bioevaluation of 22-hydroxyacuminatine analogs. |
AID321561 | Antiproliferative activity against human DU145 cells at 2 uM after 96 hrs | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 | Synthesis and bioevaluation of 22-hydroxyacuminatine analogs. |
AID366208 | Inhibition of human recombinant topoisomerase 1 assessed as DNA cleavage relative to 1 uM camptothecin | 2008 | Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15 | Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors. |
AID321556 | Cytotoxicity against mouse P388 cells | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 | Synthesis and bioevaluation of 22-hydroxyacuminatine analogs. |
AID260511 | Cytotoxicity against P388 murine leukemic cell line | 2006 | Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4 | Total synthesis and biological evaluation of 22-hydroxyacuminatine. |
AID321557 | Cytotoxicity against human KB cells | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 | Synthesis and bioevaluation of 22-hydroxyacuminatine analogs. |
AID321559 | Antiproliferative activity against human MIA PaCa cells after 96 hrs | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6 | Synthesis and bioevaluation of 22-hydroxyacuminatine analogs. |
AID260512 | Cytotoxicity against topoisomerase 1-deficient subclone P388/CPT45 murine leukemic cell line | 2006 | Journal of medicinal chemistry, Feb-23, Volume: 49, Issue:4 | Total synthesis and biological evaluation of 22-hydroxyacuminatine. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |